3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
970
Neoplasms
767
Carcinoma, Non-Small-Cell Lung
750
Prostatic Neoplasms
577
Colorectal Neoplasms
503
Lung Neoplasms
447
Neoplasm Metastasis
408
Multiple Myeloma
376
Leukemia, Myeloid, Acute
358
Ovarian Neoplasms
311
Pancreatic Neoplasms
306
Melanoma
275
Squamous Cell Carcinoma of Head and Neck
259
Recurrence
248
Carcinoma, Hepatocellular
233
Glioblastoma
225
Brain Neoplasms
221
Head and Neck Neoplasms
202
Triple Negative Breast Neoplasms
200
Carcinoma, Renal Cell
200
Lymphoma
192
Precursor Cell Lymphoblastic Leukemia-Lymphoma
191
Stomach Neoplasms
189
Endometrial Neoplasms
179
Lymphoma, Non-Hodgkin
175
Sarcoma
169
Glioma
168
Uterine Cervical Neoplasms
167
Lymphoma, Large B-Cell, Diffuse
160
Hematologic Neoplasms
159
Interventions
pembrolizumab
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urinary Bladder Diseases
×
90 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled